H.C. Wainwright Reiterates Buy Rating on Generate Biomedicines (GENB)

September 9, 2026 7:28 AM EDT Send to a Friend
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $30.00 price target on Generate Biomedicines (NASDAQ: GENB).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login